{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:15:10Z","timestamp":1776503710662,"version":"3.51.2"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":788,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1093\/annonc\/mdx392","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T03:05:53Z","timestamp":1500260753000},"page":"2047-2049","source":"Crossref","is-referenced-by-count":10,"title":["Revival of PI3K inhibitors in non-Hodgkin\u2019s lymphoma"],"prefix":"10.1016","volume":"28","author":[{"given":"C.L.","family":"Batlevi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Younes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx392_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdx392_bb0015","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"P110delta, a novel phosphoinositide 3-kinase in leukocytes","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdx392_bb0020","doi-asserted-by":"crossref","first-page":"554.","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1093\/annonc\/mdx392_bb0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","article-title":"Mutant PIK3CA promotes cell growth and invasion of human cancer cells","volume":"7","author":"Samuels","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdx392_bb0030","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-04-4114","article-title":"Functional analysis of PIK3CA gene mutations in human colorectal cancer","volume":"65","author":"Ikenoue","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx392_bb0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1073\/pnas.0408864102","article-title":"Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic","volume":"102","author":"Kang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdx392_bb0040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","article-title":"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling","volume":"125","author":"Knight","year":"2006","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdx392_bb0045","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1232","article-title":"PI 3-kinase p110beta: a new target for antithrombotic therapy","volume":"11","author":"Jackson","year":"2005","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdx392_bb0050","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.287.5455.1049","article-title":"Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation","volume":"287","author":"Hirsch","year":"2000","journal-title":"Science"},{"key":"10.1093\/annonc\/mdx392_bb0055","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1182\/blood-2003-05-1667","article-title":"Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue","volume":"103","author":"Puri","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx392_bb0060","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1038\/sj.emboj.7600361","article-title":"Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice","volume":"23","author":"Del Prete","year":"2004","journal-title":"EMBO J"},{"key":"10.1093\/annonc\/mdx392_bb0065","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"10.1093\/annonc\/mdx392_bb0070","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx392_bb0075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous Inhibition of PI3Kdelta and PI3Kalpha Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-kappaB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdx392_bb0080","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3\u2032-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx392_bb0085","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","article-title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx392_bb0090","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdx392_bb0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2437_57","article-title":"DYNAMO: a phase 2 study demonstrating the clinical activity of duvelisib in patients with double refractory indolent non-Hodgkin lymphoma","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdx392_bb0100","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx392_bb0105","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Griner","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdx392_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2437_38","article-title":"Phase I\/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed\/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma","volume":"35","author":"Batlevi","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdx392_bb0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hon.2437_39","article-title":"Updated results of a multicenter phase I\/IB study of TGR-1202 in combination with ibrutinib in patients with relapsed or refractory MCL or CLL","volume":"35","author":"Davids","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1093\/annonc\/mdx392_bb0120","doi-asserted-by":"crossref","first-page":"e1593.","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1093\/annonc\/mdx392_bb0125","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1493.1493","article-title":"An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), Mantle cell lymphoma (MCL) and follicular lymphoma (FL)","volume":"126","author":"Younes","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx392_bb0130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx392_bb0135","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx392_bb0140","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1093\/annonc\/mdx392_bb0145","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"Results of a phase I study of idelalisib, a PI3K\u03b4 inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419352706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419352706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/9\/2047\/19710044\/mdx392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T01:43:46Z","timestamp":1659231826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419352706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0923753419352706"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx392","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}